Issue 1/2012
Content (32 Articles)
A systematic approach to the management of patients with brain metastases of known or unknown primary site
Athanassios P. Kyritsis, Sofia Markoula, Victor A. Levin
Population pharmacokinetics of PM00104 (Zalypsis®) in cancer patients
Carlos Pérez-Ruixo, Belén Valenzuela, Carlos Fernández Teruel, Mario González-Sales, Bernardo Miguel-Lillo, Arturo Soto-Matos, Juan José Pérez-Ruixo
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine
M. Joerger, J. A. Burgers, P. Baas, V. D. Doodeman, P. H. M. Smits, R. S. Jansen, L. D. Vainchtein, H. Rosing, A. D. R. Huitema, J. H. Beijnen, J. H. M. Schellens
A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer
Zacharenia Saridaki, Nikolaos Malamos, Panagiotis Kourakos, Aristides Polyzos, Alexandros Ardavanis, Nikolaos Androulakis, Kostas Kalbakis, Lambros Vamvakas, Vassilis Georgoulias, Dimitris Mavroudis
Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients
Ninh M. La-Beck, Beth A. Zamboni, Alberto Gabizon, Hilary Schmeeda, Michael Amantea, Paola A. Gehrig, William C. Zamboni
In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin
Jinping Gan, Peggy Liu-Kreyche, W. Griffith Humphreys
5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity
Søren Astrup Jensen, Jens Benn Sørensen
Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers
Masashi Kanai, Atsushi Imaizumi, Yoshihiko Otsuka, Hiroki Sasaki, Momo Hashiguchi, Kazu Tsujiko, Shigemi Matsumoto, Hiroshi Ishiguro, Tsutomu Chiba
The marine sponge toxin agelasine B increases the intracellular Ca2+ concentration and induces apoptosis in human breast cancer cells (MCF-7)
Adriana A. Pimentel, Pimali Felibertt, Felipe Sojo, Laura Colman, Adriana Mayora, May Li Silva, Hector Rojas, Reinaldo Dipolo, Alírica I. Suarez, Reinaldo S. Compagnone, Francisco Arvelo, Ivan Galindo-Castro, Juan B. De Sanctis, Perla Chirino, Gustavo Benaim
Modification of uptake and subcellular distribution of doxorubicin by N-acylhydrazone residues as visualised by intrinsic fluorescence
Katharina Effenberger-Neidnicht, Sandra Breyer, Katharina Mahal, Florenz Sasse, Rainer Schobert
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial
Se Hyun Kim, Sang Joon Shin, Sun Young Kim, Se Hoon Lee, Young Suk Park, Se Hoon Park, Kyung Hee Lee, Tae Won Kim, Yong Sang Hong, Joong Bae Ahn
Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer
Wei-Xiang Qi, Zan Shen, Yang Yao
Hematologic adverse events associated with temozolomide
J. Lee Villano, Nathalie Letarte, Janny M. Yu, Shakir Abdur, Linda R. Bressler
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen)
Michele Reni, Stefano Cereda, Alessia Rognone, Carmen Belli, Michele Ghidini, Simonetta Longoni, Clara Fugazza, Sara Rezzonico, Paolo Passoni, Najla Slim, Giampaolo Balzano, Roberto Nicoletti, Stefano Cappio, Claudio Doglioni, Eugenio Villa
Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C14-erythromycin breath test and the antipyrine clearance test
M. Michael, C. Cullinane, A. Hatzimihalis, C. O’Kane, A. Milner, R. Booth, S. Schlicht, S. J. Clarke, P. Francis
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine
Jeffrey R. Infante, Suzanne F. Jones, Johanna C. Bendell, F. Anthony Greco, Denise A. Yardley, Cassie M. Lane, David R. Spigel, John D. Hainsworth, Howard A. Burris III
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells
Ching-Yuan Cheng, Shur-Hueih Cherng, Wen-Jun Wu, Tsung-Ying Yang, Xin-Yi Huang, Fu-Tien Liao, Ming-Fang Wu, Gwo-Tarng Sheu
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination
Michele Tavecchio, Joanne M. Munck, Celine Cano, David R. Newell, Nicola J. Curtin
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors
J. R. Infante, R. Kurzrock, J. Spratlin, H. A. Burris, S. G. Eckhardt, J. Li, K. Wu, J. M. Skolnik, L. Hylander-Gans, A. Osmukhina, D. Huszar, R. S. Herbst
Preclinical anti-angiogenesis and anti-tumor activity of SIM010603, an oral, multi-targets receptor tyrosine kinases inhibitor
Dongchun Wang, Feng Tang, Sen Wang, Zhenzhou Jiang, Luyong Zhang
Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: combined mTOR and AKT inhibitor therapy
William S. Holland, Clifford G. Tepper, Jose E. Pietri, Danielle C. Chinn, David R. Gandara, Philip C. Mack, Primo N. Lara Jr.
5, 7-Dimethoxyflavone sensitizes TRAIL-induced apoptosis through DR5 upregulation in hepatocellular carcinoma cells
Jian-Feng Yang, Jian-Guo Cao, Li Tian, Fei Liu
Montelukast attenuates side effects of cisplatin including testicular, spermatological, and hormonal damage in male rats
Ali Beytur, Osman Ciftci, Fatih Oguz, Hakan Oguzturk, Fethi Yılmaz
Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer
Junshik Hong, Minkyu Jung, Yu Jin Kim, Sun Jin Sym, Sun Young Kyung, Jinny Park, Sang Pyo Lee, Jeong Woong Park, Eun Kyung Cho, Sung Hwan Jeong, Dong Bok Shin, Jae Hoon Lee
A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects
Richat Abbas, Bruce A. Hug, Cathie Leister, Myriam El Gaaloul, Stephan Chalon, Daryl Sonnichsen
Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species
Vipul Kumar, Edgar L. Schuck, Robert D. Pelletier, Nadia Farah, Krista B. Condon, Meng Ye, Christopher Rowbottom, Belinda M. King, Zhi-Yi Zhang, Philip L. Saxton, Y. Nancy Wong
Different combination schedules of gemcitabine with endostar affect antitumor efficacy
Xing-Chen Peng, Meng Qiu, Meng Wei, Ben-Xu Tan, Jun Ge, Yu Zhao, Ye Chen, Ke Cheng, Yi Zhou, Yang Wu, Feng-Ming Gong, Qiu Li, Feng Xu, Feng Bi, Ji-Yan Liu
The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates
Leigh Marcus, Robert Murphy, Elizabeth Fox, Cynthia McCully, Raphael Cruz, Katherine E. Warren, Thorsten Meyer, Edward McNiff, Frank M. Balis, Brigitte C. Widemann
Triptolide augments the effects of 5-lipoxygenase RNA interference in suppressing pancreatic tumor growth in a xenograft mouse model
Xiaoling Ding, Xiaorong Zhou, Haifeng Zhang, Jingdan Qing, Hui Qiang, Guoxiong Zhou
A pilot pharmacologic biomarker study of busulfan and fludarabine in hematopoietic cell transplant recipients
Jeannine S. McCune, Erica L. Woodahl, Terry Furlong, Barry Storer, Joanne Wang, Shelly Heimfeld, H. Joachim Deeg, Paul V. O’Donnell
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study
Mitchell E. Gross, Lawrence Leichman, Elizabeth S. Lowe, Alan Swaisland, David B. Agus
Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma
David A. Reardon, Timothy Cloughesy, Jeremy Rich, W. K. Alfred Yung, Lotus Yung, Clifford DiLea, Jerry Huang, Margaret Dugan, William Mietlowski, Andrea Maes, Charles Conrad